Michael Celano - 18 Jan 2022 Form 4 Insider Report for Larimar Therapeutics, Inc. (LRMR)

Role
Chief Financial Officer
Signature
/s/ Jennifer Johansson, Attorney-in-fact
Issuer symbol
LRMR
Transactions as of
18 Jan 2022
Net transactions value
$0
Form type
4
Filing time
20 Jan 2022, 18:19:06 UTC
Previous filing
19 May 2021
Next filing
12 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LRMR Stock Option (Right to Buy) Award $0 +80,000 $0.000000 80,000 18 Jan 2022 Common Stock 80,000 $8.75 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests 25% on January 18, 2023, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.